BlackRock reports 4.9% stake in Coherus Oncology (CHRS)

Rhea-AI Filing Summary

Coherus Oncology, Inc. amendment to a Schedule 13G/A reports that BlackRock, Inc. beneficially owned 7,337,261 shares of Common Stock, representing 4.9% of the class. The filing lists sole voting power of 7,232,734 shares and sole dispositive power of 7,337,261. The form is signed by a BlackRock Managing Director on 04/27/2026.

Insights

Institutional Ownership Specialist

BlackRock reports a sub‑5% passive stake in Coherus Oncology.

The Schedule 13G/A amendment lists 7,337,261 shares and a 4.9% ownership position as of the filing. This indicates large institutional passive ownership below the 5% threshold that triggers different disclosure/treatment under Section 13.

Ownership is shown as sole voting and dispositive power in the filing; subsequent filings would reflect any material changes in stake or voting authority.

Key Figures

Beneficial ownership: 7,337,261 shares Percent of class: 4.9% Sole voting power: 7,232,734 shares +2 more

5 metrics

Beneficial ownership 7,337,261 shares Common Stock reported on Schedule 13G/A

Percent of class 4.9% Percent of Common Stock class

Sole voting power 7,232,734 shares Number with sole power to vote or direct the vote

Signature date 04/27/2026 Filing signed by Managing Director Spencer Fleming

CUSIP 19249H103 Identifier for Coherus Oncology common stock

Key Terms

Schedule 13G/A, Beneficially owned, Sole dispositive power

3 terms

Schedule 13G/A regulatory

"Amendment No. 6 to Schedule 13G/A reporting beneficial ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficially owned financial

"Amount beneficially owned: 7337261 appears in Item 4"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole dispositive power financial

"Sole power to dispose or to direct the disposition of: 7337261"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/27/2026 - 04:12 PM Learn about SEC filing dates

FAQ

What stake does BlackRock reported in CHRS?

BlackRock reported beneficial ownership of 7,337,261 shares of Coherus Oncology common stock, representing 4.9% of the class. The Schedule 13G/A amendment records sole voting power of 7,232,734 shares and sole dispositive power of 7,337,261.

When was the Schedule 13G/A filed for CHRS by BlackRock?

The Schedule 13G/A amendment is signed on 04/27/2026. The cover lists an effective or reporting date of 03/31/2026 tied to the Common Stock CUSIP 19249H103, with the signature dated 04/27/2026 on the filing.

Does BlackRock hold voting power over CHRS shares?

Yes. The filing shows BlackRock with sole power to vote or to direct the vote on 7,232,734 shares. It also reports sole dispositive power over 7,337,261 shares, as stated in the ownership section of the amendment.

Why is the ownership described as 4.9% rather than over 5%?

The Schedule 13G/A lists BlackRock's beneficial ownership as 4.9%, which is below the 5% reporting threshold for certain classifications. The filing states that no single person's interest exceeds five percent among listed holders.

Who signed the CHRS 13G/A amendment for BlackRock?

The amendment is signed by Spencer Fleming, listed as Managing Director, on 04/27/2026. Exhibit references include a Power of Attorney and an Item 7 exhibit relating to subsidiary identification.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 6)

Coherus Oncology, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

19249H103

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 19249H103

1

Names of Reporting Persons

BlackRock, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 7,232,734.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 7,337,261.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,337,261.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.9 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Coherus Oncology, Inc.
(b)	Address of issuer's principal executive offices: 333 Twin Dolphin Drive, Suite 600 REDWOOD CITY CA 94065
Item 2.
(a)	Name of person filing: BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)	Address or principal business office or, if none, residence: BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)	Citizenship: See Item 4 of Cover Page
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 19249H103
Item 4.	Ownership
(a)	Amount beneficially owned: 7337261
(b)	Percent of class: 4.9 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 7232734
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 7337261
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Coherus Oncology, Inc.. No one person's interest in the common stock of Coherus Oncology, Inc. is more than five percent of the total outstanding common shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BlackRock, Inc.

Signature:	Spencer Fleming
Name/Title:	Managing Director
Date:	04/27/2026

Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7